Pursuant to a special resolution passed by shareholders on March 5, 2018, the company has consolidated its capital on a one-new-share-for-eight-old-share basis. The name of the company has also been changed from Adent Capital Corp. to Khiron Life Sciences Corp.

Effective at the opening of business on Thursday, May 24, 2018, the common shares of Khiron Life Sciences will commence trading on the TSX Venture Exchange, and the common shares of Adent Capital will be delisted.

Postconsolidation and posttransactional capitalization:  unlimited number of common shares with no par value, of which 46,852,073 common shares are issued and outstanding on a postconsolidation basis

Escrow:  19,296,467 common shares and 295,115 share purchase warrants, of which 1,929,647 shares and 29,512 share purchase warrants are released at the date of this bulletin on a postconsolidation basis

Transfer agent:  TSX Trust Company (Toronto)

Trading symbol:  KHRN (new)